Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $1.44M | $1.70M |
| Cost of Revenue | N/A | N/A | N/A | $12.30M | $8.00M | $8.58M |
| Gross Profit | N/A | N/A | N/A | $-12.30M | $-6.56M | $-6.88M |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | -456.89% | -405.36% |
| Operating Expenses | $114.02M | $61.14M | $45.24M | $7.28M | $1.35M | $926.00K |
| Operating Income | $-114.02M | $-61.14M | $-45.24M | $-19.58M | $-7.91M | $-7.80M |
| Operating Margin | 0.00% | 0.00% | 0.00% | 0.00% | -550.97% | -459.93% |
| Net Income | $-102.33M | $-52.37M | $-42.86M | $-100.61M | $-7.33M | $-7.91M |
| Net Margin | 0.00% | 0.00% | 0.00% | 0.00% | -510.10% | -465.94% |
| EPS (Basic) | $-1.71 | $-1.08 | $-1.06 | $-2.63 | $-0.26 | $-0.20 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |